Astrazeneca Pharma India Ltd Q1 FY26 Results & Concall Highlights: Revenue, Margins & Order Book
Published 17 Jul 2026 | Pharmaceuticals & Biotechnology | Market Cap: ₹20.3K Cr
AstraZeneca Pharma India expects robust future growth driven primarily by oncology and biopharmaceutical portfolios. The Company reported a 32% revenue growth in FY 2024-25 and a 25% growth in profit before exceptional items and tax, signaling strong momentum.
From Astrazeneca Pharma India Ltd's Q1 FY26 earnings-call transcript · updated 23 Aug 2026.
Price
₹7,416
Market Cap
₹20.3K Cr
P/E Ratio
106.0
Revenue Rank
Margin Rank
How does Astrazeneca Pharma India Ltd rank in Pharmaceuticals & Biotechnology?
Compare Astrazeneca Pharma India Ltd against every Pharmaceuticals & Biotechnology company this quarter on revenue, margins and earnings-call signals.
Astrazeneca Pharma India Ltd — Quarterly revenue & net profit
Reported quarterly figures (₹ Cr). Latest: revenue ₹579 Cr, net profit ₹45 Cr.
Full financials →📊 Revenue & Sales Performance
Rank 2- →AstraZeneca Pharma India expects robust future growth driven primarily by oncology and biopharmaceutical portfolios.
- →Company plans multiple new product launches over the coming years, including rare disease products like Soliris.
- →The rare disease segment is an emerging focus area, aiming to build awareness and diagnosis capabilities in India, with potential to represent 15-16% of sales globally.
- →Growth in oncology has been phenomenal, with cancer portfolio currently constituting around 70%-75% of sales; diversification efforts are ongoing to balance this.
- →Revenue growth recorded was 32% in FY 2024-25; management is confident in sustaining high growth, with aspirations to double turnover every two years leading up to 2030.
- →AstraZeneca India aims to become a billion-dollar company by 2030, contributing about 1% of the global portfolio.
- →R&D investments and strategic marketing efforts will continue to support scaling and innovation.
- →The overall vision projects "sky is the limit" as long as patient-centric innovation and cause commitment continues.
📈 Profitability & Margins
Rank 3- →The Company reported a 32% revenue growth in FY 2024-25 and a 25% growth in profit before exceptional items and tax, signaling strong momentum.
- →Earnings per share (EPS) before exceptional items increased by 25%, despite a reduction after exceptional items due to strategic one-off costs.
- →Management is confident in continued growth driven by innovative product launches, particularly in Oncology and Biopharmaceuticals.
- →The rare diseases portfolio, though early-stage, is expected to grow steadily, contributing meaningfully over the next decade.
- →Investments in marketing, clinical trials, and logistics may increase operating costs in the short term but are aimed at sustaining long-term growth.
- →CAPEX and R&D investments will be aligned with growth plans, ensuring the introduction of new products benefiting patients in India.
- →The vision is robust growth without specifying exact figures, with a focus on expanding the product portfolio and market leadership.
- →Inventory build-up aligns with expected future demand, supporting sales growth and operational readiness.
🏗️ Capital Expenditure Plans
Yes- →The Company continues to evaluate investments needed in India periodically.
- →As a global company committed to India, AstraZeneca plans to make the right level of CAPEX investments over the next several years aligned with its plans for India.
- →There is a focus on supporting growth through activities like marketing, medical personnel, and logistics, which impact costs.
- →Investment in clinical trials, especially Phase IV trials for new product launches, is ongoing.
- →No specific CAPEX figures or projects were detailed, but the assurance is given that strategic and appropriate investments will be made as required.
💰 Fundraising & Capital Structure
No information📋 Order Book & Pipeline
YesKey Metrics
Revenue
Margin
Capex
Fundraise
Order Book
Frequently Asked Questions
What were Astrazeneca Pharma India Ltd Q1 FY26 results?
AstraZeneca Pharma India expects robust future growth driven primarily by oncology and biopharmaceutical portfolios. The Company reported a 32% revenue growth in FY 2024-25 and a 25% growth in profit before exceptional items and tax, signaling strong momentum.
What is Astrazeneca Pharma India Ltd share price analysis?
Astrazeneca Pharma India Ltd currently shows a moderate growth signal based on ranking data. The stock trades at a P/E of 106.0 with a market cap of ₹20,271 Cr. Investors should review the full earnings analysis for detailed insights.
Is Astrazeneca Pharma India Ltd planning capital expenditure?
The Company continues to evaluate investments needed in India periodically.
Keep Astrazeneca Pharma India Ltd on your radar — track it to get its next earnings analysis in your feed.
This analysis is AI-generated based on publicly available earnings data and concall transcripts. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.